TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Saved in:
Bibliographic Details
Title: TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Authors: Thiel KW; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA., Devor EJ; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA., Filiaci VL; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Mutch D; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO., Moxley K; Stephenson Cancer Center, Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City, OK., Alvarez Secord A; Duke University Institute, Duke University Health System, Durham, NC., Tewari KS; University of California Irvine Medical Center, Irvine, CA., McDonald ME; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA., Mathews C; Women and Infants Hospital in Rhode Island/The Warren Alpert Medical School of Brown University, Providence, RI., Cosgrove C; Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Obstetrics and Gynecology, Columbus, OH., Dewdney S; Rush University Medical Center, Gynecology, Chicago, IL., Aghajanian C; Memorial Sloan Kettering Cancer and Weill Cornell Medical Center, New York, NY., Samuelson MI; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA., Lankes HA; Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus, OH., Soslow RA; The University of New Mexico Health Sciences Center, Albuquerque, NM., Leslie KK; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA.; The University of New Mexico Health Sciences Center, Albuquerque, NM.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Oct 01; Vol. 40 (28), pp. 3289-3300. Date of Electronic Publication: 2022 Jun 03.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, American Recovery and Reinvestment Act; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.21.02506